1 – 15 of 18
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
(
- Contribution to journal › Article
-
Mark
Plasma N-terminal containing tau fragments (NTA-tau) : a biomarker of tau deposition in Alzheimer’s Disease
(
- Contribution to journal › Article
- 2022
-
Mark
APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases
(
- Contribution to journal › Scientific review
-
Mark
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum
(
- Contribution to journal › Article
- 2020
-
Mark
Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein
(
- Contribution to journal › Article
- 2019
-
Mark
α-synuclein in the pathophysiology of Alzheimer's disease
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
(
- Contribution to journal › Article
-
Mark
Aβ accumulation causes MVB enlargement and is modelled by dominant negative VPS4A
(
- Contribution to journal › Article
- 2016
-
Mark
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
(
- Contribution to journal › Article
-
Mark
A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein
(
- Contribution to journal › Article
-
Mark
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF
(
- Contribution to journal › Article
- 2015
-
Mark
Ceruloplasmin functional changes in Parkinson's disease-cerebrospinal fluid.
(
- Contribution to journal › Article
- 2014
-
Mark
SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease
(
- Contribution to journal › Article
- 2013
-
Mark
Fluid biomarkers in Alzheimer's disease - current concepts
(
- Contribution to journal › Scientific review